Enveric Biosciences Receives Notice of Allowance From U.S. Patent And Trademark Office For EVM401 Series Of Molecules For Mental Health Disorders Treatment

Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that it has received a Notice of Allowance (NOA) from the United States Patent and Trademark Office (USPTO) for a patent application pertaining to its EVM401 Series of molecules being developed as potential treatments for mental health disorders.

The USPTO issues a Notice of Allowance after making the determination that a patent should be granted from an application.